. 2022 Nov 2;21:15347354221133561. doi: 10.1177/15347354221133561

Table 1.

Characteristics of Included Studies.

First author, publication year, country	Study design¹	Participants at baseline; number of females; mean age		Cancer location, stage	Intervention		Survival measure
First author, publication year, country	Study design¹	Verum	Control	Cancer location, stage	Verum	Control	Survival measure
RCTs
Brinkmann,¹⁵ 2004, Germany²	Single center	37; 11; 63	37; 13; 62	Renal cell, 3-4	Eurixor	IFN-α 2b, IL-2, 5-FU	OS, RR
Cazacu,²⁰ 2003, Romania	Single center, 3 arms	29; n/a; n/a	B: 21; n/a; n/a; C:14; n/a; n/a	Colorectal, 3-43	Isorel, 5-FU, surgery	B: 5-FU, surgery; C: surgery	OS
Douwes,¹⁶ 1986, Germany	Single center, 3 arms	20; 10; 59	B: 20; 12; 60; C: 20; 11; 61	colorectal, 4	Helixor, 5-FU	B: Neo-Tumorin, 5-FU; C: 5-FU	OS, RR
Douwes,²¹ 1988, Germany⁴	Single center	20; n/a; 60	20; n/a; 56	Colorectal, 4	Helixor, 5-FU	5-FU	OS
Goebell,²² 2002, Germany	Single center	23; 6; 65	22; 5; 65	Bladder, 1-2	Lektinol	No treatment	DFS
Gutsch,¹⁷ 1988, Germany³,⁴	Multi center, 3 arms	192; 192; 60	B: 274; 274; 62; C: 177; 177; 62	Breast, 1-3	Helixor, ctx	B: ctx; C: no treatment	OS
Heiny,²³ 1997, Germany	Single center	38; 16; 55	41; 18; 53	Colorectal, 4	Eurixor, 5-FU	5-FU	OS, RR, DFS
Lange,²⁴ 1988, Germany	Single center	23; 9; 58	21; 9; 60	Ovary, lung, n/a	Helixor, ctx	ctx	RR, DR
Lenartz,²⁵ 2000, Germany	Single center	20; n/a; n/a	18; n/a; n/a	Glioma, n/a	Eurixor, cot	cot	OS, DFS
Steuer-Vogt,²⁷ 2001, Germany³	Multi center	235; 21; 55	242; 19; 55	Head, neck, 1-4	Eurixor, surgery, ctx	Surgery, ctx	DFS
Tröger,²⁶ 2016, Serbia	Single center	34; 34; 50	31; 31; 52	Breast, 1-3	Helixor, ctx	ctx	RR
NRSIs
Axtner,²⁸ 2016, Germany	Multi center	90; 44; 66	105; 57; 68	Pancreatic, 3-4	uME, ctx	ctx	OS
Beuth,²⁹ 2008, Germany	Multi center	167; 167; 55	514; 514; 55	Breast, 1-3	Helixor, cot	cot	RR, DR
Boie,³⁰ 1980, Germany	Multi center	27; n/a; n/a	39; n/a; n/a	Colorectal, n/a	Helixor	No treatment	OS, DR
Elsässer-Beile,¹⁴ 2005, Germany²	Single center, prospective	30; 7; 70	18; n/a; n/a	Bladder, 1-2	Lektinol	Bacillus Calmette-Guerin	RR
Prediger,³¹ 1956, Germany	Single center	75; 75; n/a	88; 86; n/a	Genital, n/a	Lektinol, rt	rt	OS, DR
Schad,³² 2018, Germany	Multi center	43; 18; 64	100; 43; 64	Lung, 4	uME, cot	cot	OS
Schumacher,³³ 2003, Germany	Multi center	219; 219; 60	470; 470; 64	Breast, 1-4	Eurixor, cot	cot	DFS
Thronicke,³⁴ 2020, Germany	Multi center	34; 17; 65	235; 95; 69	Lung, 1-3a	uME, ctx	ctx	OS

Abbreviations: OS, overall survival; RR, relapse rate; DFS, disease free survival; DR, death rate; cot, conventional oncological treatment; ctx, chemotherapy; rt, radiation therapy.

All studies are not blinded and with 2 arms if not stated otherwise, all RCTs are prospective; all NRSIs are retrospective if not stated otherwise.

This study compares uME with an active comparator and is only included in the sensitivity analysis.

Survival data for subgroups available.

⁴

Randomization process is reported as incomplete.